JLE

European Journal of Dermatology

MENU

Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma Volume 31, numéro 1, January-February 2021

Auteurs
1 Unit of Dermatology, University of Padua, Padua, Italy
2 Melanoma and Soft Tissue Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy

Basal cell carcinoma (BCC) is the most common human cancer. The response to currently available systemic therapies for locally-advanced or metastatic disease is usually of limited duration [1]. Recently, it was reported that advanced BCC can be responsive to systemic immunotherapy based on programmed cell death protein-1 (PD-1) inhibitors [2-4]. We report a patient with multiple superficial BCCs persisting during treatment for metastatic melanoma with the anti-PD-1 monoclonal antibody, pembrolizumab.In [...]